文献速递复苏、休克与脓毒症

院外心脏骤停的骨内或静脉血管通路

Intraosseous or Intravenous Vascular Access for Out-of-Hospital Cardiac Arrest.
PubMed 文献 · N Engl J Med · 2024-10-31
一句话结论成人非创伤性院外心脏骤停中,骨内通路与静脉通路的持续自主循环恢复无显著差异。

这项随机临床试验比较了成人非创伤性院外心脏骤停中初始骨内通路与静脉通路的有效性。主要终点为持续自主循环恢复,骨内组221例(30%)vs 静脉组214例(29%),风险比1.06(95%CI 0.90-1.24,P=0.49),无显著差异。30天生存率骨内组12% vs 静脉组10%(风险比1.16,95%CI 0.87-1.56),30天良好神经功能结局骨内组9% vs 静脉组8%(风险比1.16,95%CI 0.83-1.62)。预定不良事件不常见。

要点

  • 持续自主循环恢复:骨内组221例(30%)vs 静脉组214例(29%),风险比1.06(95%CI 0.90-1.24,P=0.49),无显著差异。
  • 30天生存:骨内组85例(12%)vs 静脉组75例(10%),风险比1.16(95%CI 0.87-1.56)。
  • 30天良好神经功能结局(改良Rankin量表0-3分):骨内组67例(9%)vs 静脉组59例(8%),风险比1.16(95%CI 0.83-1.62)。
  • 两次尝试内成功建立血管通路:骨内组669例(92%)vs 静脉组595例(80%)。
  • 预定不良事件不常见。

适用人群与场景

  • 成人非创伤性院外心脏骤停患者。

研究设计与关键结果

  • 随机临床试验,纳入1506例随机化患者,1479例纳入主要分析(骨内通路组731例,静脉通路组748例)。
  • 主要终点持续自主循环恢复:骨内组221例(30%)vs 静脉组214例(29%),风险比1.06(95%CI 0.90-1.24,P=0.49)。
  • 关键次要终点30天生存:骨内组85例(12%)vs 静脉组75例(10%),风险比1.16(95%CI 0.87-1.56)。
  • 关键次要终点30天良好神经功能结局(改良Rankin量表0-3分):骨内组67例(9%)vs 静脉组59例(8%),风险比1.16(95%CI 0.83-1.62)。
  • 两次尝试内成功建立血管通路:骨内组669例(92%)vs 静脉组595例(80%)。
  • 预定不良事件不常见。

证据类型、等级与局限

  • 证据类型:随机临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文结论:成人院外心脏骤停中,初始骨内通路与静脉通路的持续自主循环恢复无显著差异。

指南或共识出处

  • IVIO试验,EU Clinical Trials Register编号2022-500744-38-00,ClinicalTrials.gov编号NCT05205031;由Novo Nordisk Foundation等资助。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Out-of-hospital cardiac arrest is a leading cause of death worldwide. Establishing vascular access is critical for administering guideline-recommended drugs during cardiopulmonary resuscitation. Both the intraosseous route and the intravenous route are used routinely, but their comparative effectiveness remains unclear.

METHODS: We conducted a randomized clinical trial to compare the effectiveness of initial attempts at intraosseous or intravenous vascular access in adults who had nontraumatic out-of-hospital cardiac arrest. The primary outcome was a sustained return of spontaneous circulation. Key secondary outcomes were survival at 30 days and survival at 30 days with a favorable neurologic outcome, defined by a score of 0 to 3 on the modified Rankin scale (scores range from 0 to 6, with higher scores indicating greater disability).

RESULTS: Among 1506 patients who underwent randomization, 1479 were included in the primary analysis (731 in the intraosseous-access group and 748 in the intravenous-access group). The successful establishment of vascular access within two attempts occurred in 669 patients (92%) assigned to the intraosseous-access group and in 595 patients (80%) assigned to the intravenous-access group. Sustained return of spontaneous circulation occurred in 221 patients (30%) in the intraosseous-access group and in 214 patients (29%) in the intravenous-access group (risk ratio, 1.06; 95% confidence interval [CI], 0.90 to 1.24; P = 0.49). At 30 days, 85 patients (12%) in the intraosseous-access group and 75 patients (10%) in the intravenous-access group were alive (risk ratio, 1.16; 95% CI, 0.87 to 1.56); a favorable neurologic outcome at 30 days occurred in 67 patients (9%) and 59 patients (8%), respectively (risk ratio, 1.16; 95% CI, 0.83 to 1.62). Prespecified adverse events were uncommon.

CONCLUSIONS: There was no significant difference in sustained return of spontaneous circulation between initial intraosseous and intravenous vascular access in adults who had out-of-hospital cardiac arrest. (Funded by the Novo Nordisk Foundation and others; IVIO EU Clinical Trials Register number, 2022-500744-38-00; ClinicalTrials.gov number, NCT05205031.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Vallentin MF, Granfeldt A, Klitgaard TL, et al. Intraosseous or Intravenous Vascular Access for Out-of-Hospital Cardiac Arrest. N Engl J Med. 2024. PMID: 39480221. doi:10.1056/NEJMoa2407616

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。